REG - Cambridge Nutrition. - Omega Diagnostics Summons Update

Cambridge Nutritional SciencesAnnouncement

19/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250319:nRSS2012Ba&default-theme=true

RNS Number : 2012B  Cambridge Nutritional Sciences PLC  19 March 2025

Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

Omega Diagnostics Summons Update

 

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical
diagnostics company focused on promoting a personalised and functional
approach to health and nutrition, today provides an update in relation to the
summons for its subsidiary Omega Diagnostics Limited ("ODL") regarding a
historical breach of Health & Safety regulations arising from the facility
used by Omega South West, which ODL sold in 2018.  Further details of the
summons were disclosed in the Company's announcement of 21 January 2025.

Further to the summons, ODL appeared in Exeter Magistrates Court yesterday and
entered a guilty plea to all charges.   It was confirmed that the sentencing
hearing is to be held on 22 May 2025.

As noted previously, the facility in question was sold in 2018 and in the
same year Omega South West ceased all trading activities. This entity has
not formed any part of the Company's ongoing operations or business model and
there are currently no employees within the Company who had any dealings or
involvement with Omega South West.

Further announcements will be made as and when appropriate.

 

Contacts:

 

 Cambridge Nutritional Sciences plc                            www.cnsplc.com (http://www.cnsplc.com/)
 Carolyn Rand, Non-Executive Chair
 James Cooper, Interim Chief Executive

 Cavendish Capital Markets Limited                           Tel: 020 7220 0500
 Geoff Nash / Edward Whiley (Corporate Finance)
 Nigel Birks / Harriet Ward (ECM)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPKFBBKBKBOND